| Drug Name | Olican (fingolimod) |
|---|---|
| Drug Class |
Immunosuppressant
|
| Risk minimization type |
Direct Healthcare Professional Communication DHPC
|
| Specialty (Theraputic area) |
Neurology
|
| Risk |
Olican® (fingolimod) – Updated recommendations to minimise the risk of druginduced liver injury (DILI) |
| Dear Healthcare provider letter DHPC |
|